Agilon Health Inc (AGL) concluded trading on Thursday at a closing price of $2.22, with 4.05 million shares of worth about $8.99 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -67.83% during that period and on December 12, 2024 the price saw a gain of about 11.56%. Currently the company’s common shares owned by public are about 411.96M shares, out of which, 303.41M shares are available for trading.
Stock saw a price change of 0.45% in past 5 days and over the past one month there was a price change of 18.72%. Year-to-date (YTD), AGL shares are showing a performance of -82.31% which decreased to -81.98% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.50 but also hit the highest price of $13.76 during that period. The average intraday trading volume for Agilon Health Inc shares is 4.55 million. The stock is currently trading 11.31% above its 20-day simple moving average (SMA20), while that difference is down -10.43% for SMA50 and it goes to -52.69% lower than SMA200.
Agilon Health Inc (NYSE: AGL) currently have 411.96M outstanding shares and institutions hold larger chunk of about 80.57% of that.
The stock has a current market capitalization of $914.68M and its 3Y-monthly beta is at 0.52. It has posted earnings per share of -$0.82 in the same period. It has Quick Ratio of 1.29 while making debt-to-equity ratio of 0.08. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AGL, volatility over the week remained 9.03% while standing at 9.50% over the month.
Stock’s fiscal year EPS is expected to drop by -17.47% while it is estimated to increase by 33.15% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Bernstein on December 11, 2024 offering a Mkt perform rating for the stock and assigned a target price of $2.50 to it. On November 08, 2024, William Blair Downgrade their recommendations, while on October 30, 2024, Citigroup Downgrade their ratings for the stock with a price target of $2.50. Stock get an Underperform rating from BofA Securities on October 02, 2024.
